Healthcare / Medical Instruments & SuppliesTaipei Exchange
$79.20
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $461.2M · quality 83.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.7B
P/E
15.1x
↓EV/EBITDA
8.7x
↓ROE
12.9%
↑Gross Margin
30.7%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.3%
FCF CAGR
+5.4%
FCF margin
19.2%
FCF / Net income
1.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.41B · net income $382.9M · FCF $461.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.41B | $2.41B | $2.35B | $2.32B | $2.18B |
| Net Income | $382.9M | $382.9M | $447.8M | $420.8M | $331.4M |
| EBITDA | $621.2M | $621.2M | $705.4M | $674.1M | $568.9M |
| EPS | 5.24 | 5.24 | 6.13 | 5.76 | 4.54 |
| Gross Margin | 30.7% | 30.7% | 31.8% | 31.9% | 26.9% |
| Operating Margin | 19.7% | 19.7% | 20.9% | 21.5% | 16.2% |
| Net Margin | 15.9% | 15.9% | 19.1% | 18.1% | 15.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.15 | 0.15 | 0.16 |
| Current Ratio | 3.49 | 3.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $461.2M | $461.2M | $456.6M | $620.7M | $394.1M |
| Returns | |||||
| ROE | 12.9% | 12.9% | 15.2% | 14.9% | 12.2% |
| Valuation | |||||
| P/E | 15.11 | 15.11 | 15.69 | 15.23 | 16.15 |
| EV/EBITDA | 8.68 | 8.68 | 9.52 | 9.05 | 8.97 |
| P/B | 1.95 | 1.95 | 2.39 | 2.26 | 1.97 |
| Growth & Yield | |||||
| Revenue Growth | 2.6% | 2.6% | 1.1% | 6.2% | — |
| EPS Growth | -14.5% | -14.5% | 6.4% | 26.9% | — |
| Dividend Yield | 6.3% | 6.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
10.3%
EPS terminal req.
$7.03
Spread vs growth
-24.8%
5Y implied EPS CAGR
10.2%
EPS terminal req.
$8.50
Spread vs growth
-24.7%
10Y implied EPS CAGR
10.1%
EPS terminal req.
$13.69
Spread vs growth
-24.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.4%
Start / end P/E
15.1x → 15.1x
EPS bridge
6.13 → 5.24
Residual
+0.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.